PARP Inhibition in Recurrent Ovarian Cancer

Abstract: With the introduction of PARP inhibitors into frontline chemotherapy, with or without bevacizumab, the hope exists that more women may be spared a recurrence […]

PARP Inhibition as Frontline Therapy in Ovarian Cancer

Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors have been rapidly integrated into clinical practice for women with ovarian cancer. Currently, PARP inhibitors are approved as frontline maintenance […]